News

In articles for industry publications WCI Weekly and WorkersCompensation.com, myMatrixx experts highlighted some of the key takeaways from the newly released 2020 Drug Trend Report.

The U.S. Food and Drug Administration (FDA) approved Kloxxado™ (naloxone) nasal spray, 8mg, on April 29, 2021.

In the wake of an unprecedented year for workers’ compensation pharmacy, myMatrixx was able to achieve positive outcomes, according to the newly released 2020 Drug Trend Report.

On Wednesday April 14, myMatrixx Chief Clinical Officer, Phil Walls, was joined by Marcos Iglesias MD, Chief Medical Director of the Travelers and Constitution State Services to discuss the interaction between behavioral health and chronic pain management in workers’ compensation.

Evernorth announced the acquisition of MD LIVE, a leading provider of virtual healthcare services in the U.S. with more than 60 million members nationwide.

Wednesday, April 28, will be Workers’ Memorial Day, created as an international day of mourning and remembrance for workers who have been killed or seriously injured on the job.

myMatrixx is proud to have had two entries accepted into the Virtual Poster Hall and Speakership exhibit for the 2021 National Rx Drug Abuse & Heroin Summit.

myMatrixx Chief Clinical Officer, Phil Walls, recently appeared in a piece for Risk & Insurance on the important lessons the COVID-19 pandemic has taught workers’ compensation about behavioral health and psychotropic drug use.

myMatrixx releases 2021 guidebook aimed at providing a quick reference resource on prior authorization medications and generic drug availability.

On February 27, 2021, Emergency Use Authorization (EUA) was granted to Janssen’s (Johnson & Johnson) COVID-19 vaccine (Ad26.COV2.S), by the U.S. Food and Drug Administration (FDA).